首次人体 ENCIT01 试验：比较第二代与第三代 L1CAM 特异性 CAR-T 细胞治疗原发难治或复发神经母细胞瘤患者

The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed

尽管在经重度预处理的人群中可进行生产，L1CAM 可能并不是神经母细胞瘤的合适靶点。

癌胎抗原作为嵌合抗原受体 (CAR)-T 细胞免疫治疗的新兴靶点：机遇与挑战

Oncofetal antigens as emerging targets in chimeric antigen receptor (CAR)-T cell-based immunotherapies: opportunities and challenges.

整合 CD28、4-1BB 和 CD27 的三重共刺激 GD2-CAR-T 细胞在实体瘤模型中介导强效细胞毒性并减少耗竭

Triple-costimulatory GD2-CAR T cells incorporating CD28, 4-1BB and CD27 mediate potent cytotoxicity and reduce exhaustion in solid tumour models.

间变性淋巴瘤激酶阳性儿童肿瘤的靶向免疫治疗：当前进展与未来展望

Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives.

免疫 PET 引导的抗原分层 CAR-T 细胞治疗神经母细胞瘤

ImmunoPET-guided, antigen-stratified CAR T-cell therapy for neuroblastoma.

FECH：影响 CAR-T 细胞表型与功能的新型代谢靶点

FECH, a novel metabolic target influencing CAR T-cell phenotype and function.

精准医学在神经母细胞瘤中的作用：靶向治疗与个体化方法——叙述性综述

The Role of Precision Medicine in Neuroblastoma: Targeted Therapies and Personalized Approaches-A Narrative Review.

精准医学通过提高诊断特异性和治疗效果并降低毒性，改变了神经母细胞瘤的治疗。在新兴策略中，ALK 靶向治疗和抗 GD2 免疫治疗显示出强大的临床潜力，尽管仍需进一步验证以改善患病儿童的生存率和生活质量。

EZH2 抑制剂他泽司他（tazemetostat）在尤因肉瘤中模型依赖性的 GD2 上调：与 GD2 特异性 CAR-T 细胞联合的前提条件

Model-dependent GD2 upregulation in Ewing sarcoma with the EZH2 inhibitor tazemetostat: Prerequisites for combination with GD2-specific CAR T cells.

放射性药物通过肿瘤增敏与肿瘤微环境重塑增强 CAR-T 细胞对放射敏感及放射抵抗神经母细胞瘤的作用

A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling.

开发针对神经母细胞瘤的新型 GPC2 靶向放射诊疗和 CAR-T 细胞疗法

Development of novel GPC2-directed radiotheranostics and CAR T cell therapy for neuroblastoma.